GlobeNewswire Inc. · Jul 1, 2024
Viridien : Informations relatives au nombre total de droits de vote et d'actions
Viridien
VI
NASDAQ · VIRI
Virios Therapeutics, Inc.
Healthcare · Biotechnology
$0.16
Up+$0.02 (+12.40%)
Updated Aug 21, 2026, 9:23 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 206.5K
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 42.36M
- Avg. volume
- 89.79K
Price performance
VIRI price history
1M range · 0 trading sessions · Daily adjusted prices
VIRI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest VIRI news
The latest Smart Investors Daily articles mentioning VIRI.
Stock researchCompany · Overview
VIRI research
Overview
Company profile and research snapshot.
Company profile
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2024 | HC Wainwright & Co. | Neutral | — |
| Aug 9, 2024 | HC Wainwright & Co. | Neutral | — |
| Jun 20, 2024 | Maxim Group | Buy | — |
| Sep 20, 2022 | HC Wainwright & Co. | Neutral | — |
| Dec 15, 2021 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Jul 1, 2024
Viridien: Information on the total number of voting rights and shares
Viridien
GlobeNewswire Inc. · Jun 27, 2024
Viridien: Launch of Viridien reverse share split
Launch of Viridien (ex-CGG) reverse share split
GlobeNewswire Inc. · Jun 27, 2024
Viridien : Lancement du regroupement des actions Viridien
Lancement du regroupement des actions Viridien (ex-CGG)
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
